7-甲基鸟苷 | 15313-37-8

• 物质功能分类: 生物化工 - 核苷类药物 - 核苷中间体
• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 中文名称: 7-甲基鸟苷
• 中文别名: 7,8-二氢-7-甲基鸟苷
• 英文名称: 7-methyl-guanosine
• 英文别名: N7-Methylguanosine；2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-methyl-3,8-dihydropurin-6-one；2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-methyl-1,8-dihydropurin-6-one
• CAS: 15313-37-8
• 化学式: C₁₁H₁₇N₅O₅
• 分子量: 299.286
• InChiKey: ZBDDPUHBOFHFRK-KQYNXXCUSA-N

物化性质

• 熔点：
  >180°C (dec.)
• 密度：
  2.03±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO（少许）、水（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  144
• 氢给体数：
  5
• 氢受体数：
  8

安全信息

• 安全说明：
  S22,S24/25
• WGK Germany：
  3
• 储存条件：
  -20°C

反应信息

• 作为反应物：
  描述：

  7-甲基鸟苷 在 phosphate buffer 、 E_. coli purine nucleoside phosphorylase 、 磷酸肌酸 作用下， 以 水 为溶剂， 生成 2-amino-7-methyl-8,9-dihydro-1H-purin-6-one 、 α-D-ribofuranosyl-1-phosphate
  参考文献：
  名称：

  Synthesis of 2-Chloro-6-aryloxy- and 2-Chloro-6-alkoxyarylpurines and Their Properties in the Purine Nucleoside Phosphorylase (PNP) System

  摘要：

  A seri es of 2-chloro-6-aryloxy- and 2-chloro-6-alkoxyarylpurines was synthesized and their kinetic properties in the purine nucleoside phosphorylase (PNP) system were determined. All compounds showed inhibitory activity (IC50 in the range 0.5-76 mu M) vs. hexameric ("high-molecular weight") PNP from E. coli. By contrast, no inhibition vs. trimeric Cellulomonas PNP was detected.

  DOI：

  10.1080/15257779908041587
• 作为产物：
  描述：

  鸟苷 、 硫酸二甲酯 以 N,N-二甲基乙酰胺 为溶剂， 反应 6.0h， 以86%的产率得到7-甲基鸟苷
  参考文献：
  名称：

  Syntheses of [6,7-15N]-Adenosine, [6,7-15N]-2'-Deoxyadenosine, and [7-15N]-Hypoxanthine

  摘要：

  We have developed a high-yield route for the synthesis of [7-N-15]-hypoxanthine in four steps in an overall yield of 81%. This procedure uses [N-15]-sodium nitrite as the N-15 source and an inexpensive pyrimidine to provide an economical route to this useful N-15-labeled intermediate. Conversion to [7-N-15]-6-chloropurine followed by enzymatic transglycosylation gives the corresponding ribo- and 2'-deoxyribonucleosides. Ammonolysis of the 6-chloro moiety to give the [6,7-N-15]-labeled nucleosides is effected simply and in high yield using 2 equiv of [N-15]-ammonium chloride and 3 equiv of potassium bicarbonate.

  DOI：

  10.1021/ja00152a006

文献信息

• POLY(PHOSPHOESTERS) FOR DELIVERY OF NUCLEIC ACIDS
  申请人：TRANSLATE BIO, INC.

  公开号：US20200277446A1

  公开（公告）日：2020-09-03

  Disclosed are polymers comprising the moiety A, which is a moiety of formula I: and pharmaceutically acceptable salts thereof, wherein R, R 1 , R 2 , L, n1 and n2 are as defined herein. These polymers are useful for delivering nucleic acids to subject. These polymers and pharmaceutically acceptable compositions comprising such polymers and nucleic acids can be useful for treating various diseases, disorders and conditions.

  揭示了包含A基团的聚合物，该基团是化学式I的基团：及其药用可接受的盐，其中R、R1、R2、L、n1和n2如本文所定义。这些聚合物对于将核酸传递给受试者是有用的。这些聚合物和包含这些聚合物和核酸的药用可接受组合物可用于治疗各种疾病、疾病和症状。
• [EN] AMIDOIMIDAZOPYRIDAZINES AS MKNK-1 KINASE INHIBITORS<br/>[FR] AMIDOIMIDAZOPYRIDAZINES À TITRE D'INHIBITEURS DE KINASES MKNK-1
  申请人：BAYER PHARMA AG

  公开号：WO2014118135A1

  公开（公告）日：2014-08-07

  The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I) : in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper- proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及一般式(I)的酰胺取代咪唑吡啶化合物，其中A、R1、R2、R3、R4和n如权利要求中所定义，以及制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包括所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是用作唯一药剂或与其他活性成分结合。
• [EN] COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS<br/>[FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS DE SYNTHÈSE
  申请人：WAVE LIFE SCIENCES LTD

  公开号：WO2018237194A1

  公开（公告）日：2018-12-27

  The present disclosure, among other things, provides technologies for synthesis, including reagents and methods for stereoselective synthesis. In some embodiments, the present disclosure provides compounds useful as chiral auxiliaries. In some embodiments, the present disclosure provides reagents and methods for oligonucleotide synthesis. In some embodiments, the present disclosure provides reagents and methods for chirally controlled preparation of oligonucleotides. In some embodiments, technologies of the present disclosure are particularly useful for constructing challenging internucleotidic linkages, providing high yields and stereoselectivity.

  本公开内容提供了合成技术，包括用于立体选择性合成的试剂和方法。在某些实施例中，本公开内容提供了作为手性辅助剂有用的化合物。在某些实施例中，本公开内容提供了用于寡核苷酸合成的试剂和方法。在某些实施例中，本公开内容提供了用于手性控制寡核苷酸制备的试剂和方法。在某些实施例中，本公开内容的技术特别适用于构建具有挑战性的核苷酸间连接，提供高产率和立体选择性。
• [EN] COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES<br/>[FR] ASSOCIATION DE VACCINS CONTRE LE VIRUS DE L'HÉPATITE B (VHB) ET DE DÉRIVÉS DE PYRIDOPYRIMIDINE
  申请人：JANSSEN SCIENCES IRELAND UNLIMITED CO

  公开号：WO2020255038A1

  公开（公告）日：2020-12-24

  Therapeutic combinations of hepatitis B virus (HBV) vaccines and a pyridopyrimidine derivative are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the disclosed therapeutic combinations are also described. The invention provides therapeutic combinations or compositions and methods for inducing an immune response against hepatitis B viruses (HBV) infection.

  本发明描述了乙型肝炎病毒（HBV）疫苗和吡啶吡嘧啶衍生物的治疗组合。还描述了利用所述治疗组合诱导免疫应答对抗HBV或治疗HBV引起的疾病的方法，特别是在患有慢性HBV感染的个体中。该发明提供了用于诱导免疫应答对抗乙型肝炎病毒（HBV）感染的治疗组合或组成物和方法。
• [EN] AMINOIMIDAZOPYRIDAZINES<br/>[FR] AMINOIMIDAZOPYRIDAZINES
  申请人：BAYER PHARMA AG

  公开号：WO2014076162A1

  公开（公告）日：2014-05-22

  The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I), in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper- proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及一般式(I)的氨基取代咪唑吡啶化合物，其中A、R1、R2、R3、R4和n如权利要求中所定义，以及制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是用作唯一药剂或与其他活性成分组合使用时，用于治疗或预防过度增殖和/或血管生成障碍的疾病。